

28 May 2025

India | Equity Research | Results update

Gujarat Fluorochemicals

Speciality Chemicals

FY26 recovery aided by fluoropolymers and battery chemicals

Gujarat Fluorochemicals' (GFL) Q4FY25 print was impacted by lower sales of bulk chemicals with production disrupted for 20days due to incident in Dahej. It expects fluoropolymers revenue to grow 25% in FY26 with higher volume in new fluoropolymers, and steady rise in PTFE volume. R-32 capacity commissioning has been expedited, and may now start in H2FY26, therefore, supporting fluorochemicals. GFL remains confident of approvals, and contracts in battery chemicals for LiPF6 salt, and binders immediately with potential billing to commence in H2FY26. We cut our EPS for FY26/27E by 3-9% and reduce TP to INR 3,790 (from INR 4,160), valuing the stock at FY28E P/E multiple of 30x (unchanged); downgrade to **HOLD** (from Buy).

Fluoropolymers' revenue rose 10.7% YoY to INR 7.1bn

GFL's revenue was up 8.1% YoY to INR 12.3bn aided by increase in fluoropolymers segment's revenue (up 10.7% YoY) – with higher mix of value-added products. Bulk chemicals' revenue was down 8.5% YoY/11.5% QoQ to INR 1.6bn, and was impacted by 20days production shutdown due to incident in CMS-1 at Dahej, while prices for caustic soda were stable. MDC prices continue to be depressed. Fluorochemicals' revenue rose 7.9% YoY to INR 3.3bn, as ref-gas, particularly R-22, has shown price rise, but fluoro-specialty revenue was stable. Fluoropolymers' revenue increased 10.7% YoY to INR 7.1bn. Fluoropolymers' volume has grown YoY while prices have been stable.

Outlook for key business segments

1) **Fluoropolymers:** 3M closed its fluoropolymers plant in Dec'24; Solvay is partly shutting the capacity. GFL has already started receiving some volumes from industry consolidation. It anticipates volume off-take to start in FY26; it has started filling inventory across its warehouses. It has guided fluoropolymers revenue growth of 25% in FY26, which could reach optimal utilisation by end-FY26. It is adding more capacity in FY26 to support growth for future. GFL believes FKM volumes have started growing steadily with approval for new projects underway.

GFL is expecting the final approval for its PTFE and PVDF battery grade which should help grow business for binder application.

Financial Summary

Y/E March (INR mn)	FY25A	FY26E	FY27E	FY28E
Net Revenue	47,370	60,158	70,378	81,750
EBITDA	11,570	17,775	20,712	25,027
EBITDA Margin (%)	24.4	29.5	29.4	30.6
Net Profit	5,460	9,563	10,815	13,882
EPS (INR)	49.7	87.0	98.4	126.3
EPS % Chg YoY	25.5	75.2	13.1	28.4
P/E (x)	80.3	45.8	40.5	31.6
EV/EBITDA (x)	39.2	26.0	22.2	18.2
RoCE (%)	7.1	10.3	10.5	12.1
RoE (%)	8.3	12.4	12.6	14.4

Sanjesh Jainsanjesh.jain@icicisecurities.com
+91 22 6807 7153**Mohit Mishra**

mohit.mishra@icicisecurities.com

Aparajita Chakraborty

aparajita.chakraborty@icicisecurities.com

Market Data

Market Cap (INR)	438bn
Market Cap (USD)	5,130mn
Bloomberg Code	FLUOROCH IN
Reuters Code	GUJL BO
52-week Range (INR)	4,881 /2,476
Free Float (%)	37.0
ADTV-3M (mn) (USD)	4.0

Price Performance (%)	3m	6m	12m
Absolute	7.6	2.6	24.4
Relative to Sensex	(1.7)	0.9	16.2

ESG Score	2023	2024	Change
ESG score	62.9	58.8	(4.1)
Environment	44.2	45.7	1.5
Social	74.1	66.4	(7.7)
Governance	68.2	65.8	(2.4)

Note - Score ranges from 0 - 100 with a higher score indicating higher ESG disclosures.

Source: SES ESG, I-sec research

Earnings Revisions (%)	FY26E	FY27E
Revenue	(1.1)	(1.7)
EBITDA	(3.1)	(4.4)
EPS	(2.6)	(8.8)

Previous Reports22-02-2025: [Company update](#)30-01-2025: [Q3FY25 results review](#)

2) **EV:** GFL's key plants for battery chemicals including salts, electrolyte, PVDF and PTFE have stabilised, and commercial production shall commence post customer validation and long-term contracts. The company has invested INR 8bn in capex during FY25; considering the initial strong feedback, and company's encouraging internal validation, it expects to invest INR 12bn in battery chemicals (incl AHF plant) in FY26 where it will undertake phase-2 & 3 expansion. GFL anticipates revenue booking from H2FY26, and ramp up in FY27.

LFP Plant: GFL has achieved mechanical completion of LFP plant; commissioning is progressing as scheduled, with trial production likely to commence by Jun'25. **LiPF6 Salt:**

GFL has stabilised production, stringent customer specifications have been achieved, and product sampling for validation has shown a significant uptrend.

Electrolyte & Binder Plants: The electrolyte, PVDF, and PTFE binder grades have been established and are in advanced stages of customer validation. Many customers have audited the plants.

3) **Ref-gas:** The company has announced R-32 capacity addition up to 30ktpa with initial plant of 20ktpa capacity by Mar'26 with investment of INR 1.5bn. It is now working to prepone the commissioning with retro-fitting, and expedite commissioning of plant. GFL expects R-22 volume to lose from phase down, but it will be offset by pricing increase, thereby, holding on to revenue.

EBITDA up 28.8% YoY/ 4.1% QoQ to INR 3.1bn, margin at 25%

Gross profit margin improved 95bp YoY (down 590bp QoQ) to 66.3%, likely hurt by lower revenue from bulk chemicals and higher mix of ref-gas where we believe it has higher input cost (from blending R-410a). Power and fuel cost dipped 10.6% YoY (down 12.8% QoQ) to INR 1.8bn on 20days shutdown of Dahej plant; other expenses were up 3.3% YoY/ 3.2% QoQ to INR 2.2bn. EBITDA margin came in at 25% (down 63bp QoQ). Net profit rose 89.2% YoY to INR 1.9bn. Finance cost fell 22.8% YoY to INR 260mn and effective tax rate was 12% (vs 28% in Q3FY25).

Other highlights

- **Capex:** FY26 capex is anticipated at INR 16bn with INR 12bn towards battery chemicals and AHF and INR 4bn towards ref-gas and fluoropolymers.
- **Working capital:** Inventory elevated at end-FY25 due to channel filling of fluoropolymers and battery chemicals in anticipation of uptick in demand.
- **Specialty chemicals:** Company anticipates offtake to improve in FY26 with better volumes and margins.
- **Fluoropolymers:** It has invested heavily in monomer capacity with modular polymerisation capacity and requires lower capex and lead time.
- P&F cost may dip by 10–15% (up to INR 1.5bn) as it shifts towards consumption of renewables. The partial benefit will show up in FY26.
- **Battery chemicals:** The investment will be funded through external source, and GFL's cashflow will not be used for GFCL EV's growth.

Risks

Downside risk: 1) Increase in related-party transactions; and 2) execution in fluoropolymer and battery chemicals businesses.

Upside risk: 1) Upcycle in fluoropolymers with higher-than-expected pricing; and 2) better-than-expected offtake in battery chemicals.

Exhibit 1: Gujarat Fluorochemicals financials (consolidated)


INR mn	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	QoQ (%)	YoY (%)
Revenue	11,330	11,760	11,880	11,480	12,250	6.7	8.1
COGS	3,927	4,070	3,740	3,190	4,130	29.5	5.2
Gross profit	7,403	7,690	8,140	8,290	8,120	(2.1)	9.7
GPM (%)	65.3	65.4	68.5	72.2	66.3		
Employee cost	880	1,030	1,100	1,150	1,050	(8.7)	19.4
% of revenue	7.8	8.8	9.3	10.0	8.6		
Power & fuel	1,980	2,040	2,090	2,030	1,770	(12.8)	(10.6)
% of revenue	17.5	17.3	17.6	17.7	14.4		
Other expenses	2,168	2,000	2,000	2,170	2,240	3.2	3.3
% of revenue	19.1	17.0	16.8	18.9	18.3		
Total expenses	5,028	5,070	5,190	5,350	5,060	(5.4)	0.6
EBITDA	2,376	2,620	2,950	2,940	3,060	4.1	28.8
EBITDA (%)	21.0	22.3	24.8	25.6	25.0		
Depreciation	812	850	900	910	890	(2.2)	9.7
EBIT	1,564	1,770	2,050	2,030	2,170	6.9	38.7
Other income	183	90	90	140	260	85.7	42.2
Finance cost	337	370	420	420	260	(38.1)	(22.8)
PBT	1,410	1,490	1,720	1,750	2,170	24.0	53.9
Tax	401	410	510	490	260	(46.9)	(35.1)
ETR (%)	28.4	27.5	29.7	28.0	12.0		
Minority interest /JV	-	-	-	-	-		
Exceptional item	-	-	-	-	-		
Net profit	1,010	1,080	1,210	1,260	1,910	51.6	89.2
Net profit (%)	8.9	9.2	10.2	11.0	15.6		
EPS (INR)	9.2	9.8	11.0	11.5	17.4		

Source: I-Sec research, Company data

Exhibit 2: Gujarat Fluorochemicals financials (segmental)

INR mn	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	QoQ (%)	YoY (%)
Segment revenue							
Bulk chemicals	1,760	1,690	1,590	1,820	1,610	(11.5)	(8.5)
Fluorochemicals	3,020	2,970	3,040	2,930	3,260	11.3	7.9
Fluoropolymers	6,450	6,850	7,000	6,510	7,140	9.7	10.7
Other Products	100	250	250	220	240	9.1	139.3
Total	11,330	11,760	11,880	11,480	12,250	6.7	8.1
Mix (%)							
Bulk commodities	15.5	14.4	13.4	15.9	13.1		
Fluorochemicals	26.7	25.3	25.6	25.5	26.6		
Fluoropolymers	56.9	58.2	58.9	56.7	58.3		
Other Products	0.9	2.1	2.1	1.9	2.0		

Source: I-Sec research, Company data


Exhibit 3: Gross and EBITDA margins trends


Source: I-Sec research, Company data


Exhibit 4: Earnings revision

INR mn	Revised		Earlier		Change (%)	
	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Revenue	60,158	70,378	60,849	71,593	(1.1)	(1.7)
Gross profit	41,545	47,899	42,625	49,435	(2.5)	(3.1)
GPM (%)	69.1	68.1	70.0	69.0		
EBITDA	17,775	20,712	18,351	21,668	(3.1)	(4.4)
EBITDA (%)	29.5	29.4	30.2	30.3		
PAT	9,563	10,815	9,816	11,859	(2.6)	(8.8)
EPS (INR)	87.0	98.4	89.4	108.0	(2.6)	(8.8)


Source: I-Sec research

EXIM Data**Exhibit 5: PTFE prices up 8.5% YoY**


Source: I-Sec research, Commerce Ministry

Exhibit 6: PTFE-R22 spread down 55.8% YoY


Source: I-Sec research, Commerce Ministry

Exhibit 7: Other fluoropolymers prices up 3.3% YoY


Source: I-Sec research, Commerce Ministry

Exhibit 8: R-32 prices up 13.7% YoY


Source: I-Sec research, Commerce Ministry

Exhibit 9: R-134a prices up 45.4% YoY


Source: I-Sec research, Commerce Ministry

Exhibit 10: R22 prices up 21.9% QoQ/ 45% YoY


Source: I-Sec research, Commerce Ministry

Exhibit 11: R22 spread up 66.9% YoY

Source: I-Sec research, Commerce Ministry

Exhibit 12: Caustic soda prices up 20% YoY

Source: I-Sec research, Commerce Ministry

Exhibit 13: MDC (chloromethane) prices up 7.8% YoY


Source: I-Sec research, Commerce Ministry

Financials

Exhibit 14: Revenue to grow at CAGR of 21.1% over FY25–27E

INR mn	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	CAGR (%) FY25-27E
Revenue								
Bulk Chemical	7,094	10,092	11,398	6,888	6,710	7,498	7,194	3.5
Fluorochemical	6,405	6,287	15,182	10,689	12,200	14,458	17,204	18.7
Fluoropolymers	12,719	22,126	29,362	24,356	27,500	34,288	40,997	22.1
Others/Battery Chemicals	-	-	-	4	960	3,008	4,058	105.6
Total	26,219	38,504	55,942	41,937	47,370	59,251	69,453	21.1
<i>Growth (%)</i>		46.9	45.3	(25.0)	13.0	25.1	17.2	
Mix (%)								
Bulk Chemical	27.1	26.2	20.4	16.4	14.2	12.7	10.4	
Fluorochemical	24.4	16.3	27.1	25.5	25.8	24.4	24.8	
Fluoropolymers	48.5	57.5	52.5	58.1	58.1	57.9	59.0	
Others/ Battery Chemicals	-	-	-	0.0	2.0	5.1	5.8	

Source: I-Sec research, Company data

Exhibit 15: EBITDA to grow at CAGR of 33.8% over FY25–27E

INR mn	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	CAGR (%) FY25-27E
Financial								
Revenue	26,505	39,536	56,847	42,808	47,370	60,158	70,378	21.9
COGS	8,883	12,146	15,705	14,533	15,130	18,613	22,479	
Gross profit	17,622	27,390	41,141	28,275	32,240	41,545	47,899	21.9
<i>GMP (%)</i>	66.5	69.3	72.4	66.0	68.1	69.1	68.1	
<i>Growth (%)</i>		55.4	50.2	(31.3)	14.0	28.9	15.3	
Employee cost	2,179	2,655	3,221	3,504	4,330	4,980	5,577	13.5
<i>% of revenue</i>	8.2	6.7	5.7	8.2	9.1	8.3	7.9	
Other expenses	9,067	13,051	18,267	15,697	16,340	18,791	21,610	15.0
<i>% of revenue</i>	34.2	33.0	32.1	36.7	34.5	31.2	30.7	
Total expenses	10,894	15,705	21,488	19,201	20,670	23,771	27,187	14.7
EBITDA	6,729	11,685	19,653	9,074	11,570	17,775	20,712	33.8
<i>EBITDA (%)</i>	25.4	29.6	34.6	21.2	24.4	29.5	29.4	
<i>Growth (%)</i>		73.7	68.2	(53.8)	27.5	53.6	16.5	
D&A	2,021	2,054	2,361	2,861	3,550	4,014	5,132	20.2
EBIT	4,708	9,630	17,292	6,213	8,020	13,761	15,581	39.4
<i>Growth (%)</i>		104.5	79.6	(64.1)	29.1	71.6	13.2	
Other income	1,241	1,606	1,723	1,069	580	609	639	5.0
Finance cost	1,126	784	1,168	1,331	1,470	1,584	1,761	
PBT	4,824	10,452	17,847	5,951	7,130	12,785	14,459	42.4
<i>Growth (%)</i>		116.7	70.8	(66.7)	19.8	79.3	13.1	
Tax expenses	7,039	2,693	4,617	1,601	1,670	3,222	3,644	47.7
<i>ETR (%)</i>	145.9	25.8	25.9	26.9	23.4	25.2	25.2	
PAT	(2,187)	7,872	13,288	4,350	5,460	9,563	10,815	40.7
<i>Growth (%)</i>		(459.9)	68.8	(67.3)	25.5	75.2	13.1	
Adj. EPS (INR)	33.1	71.7	121.0	39.6	49.7	87.0	98.4	40.7

Source: Company data, I-Sec research

Exhibit 16: ROCE (pre-tax) to improve to 14% in FY27E

INR mn	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	CAGR (%) FY25-27E
Capital productivity								
Gross block	32,048	35,541	42,890	56,524	59,929	75,119	82,714	17.5
Revenue/GB (x)	0.83	1.11	1.33	0.76	0.79	0.80	0.85	
EBITDA/GB (x)	0.21	0.33	0.46	0.16	0.19	0.24	0.25	
Capex	2,737	6,740	6,750	9,556	8,190	15,190	7,595	
Intensity (% of revenue)	10.3	17.0	11.9	22.3	17.3	25.3	10.8	
D&A/capex (x)	0.7	0.3	0.3	0.3	0.4	0.3	0.7	
Capital employed	50,597	57,830	69,990	79,321	92,870	1,06,665	1,16,069	11.8
pre-tax ROCE (%)	9.0	17.8	27.1	8.3	9.3	13.8	14.0	
Leverage								
Net debt	11,690	11,375	13,171	17,973	14,870	23,447	22,106	
ND/EBITDA (x)	1.7	1.0	0.7	2.0	1.3	1.3	1.1	
Cash conversion								
Inventory days	119	87	95	134	140	130	130	
Debtor days	92	72	71	72	92	87	82	
Creditor days	47	47	44	44	47	47	47	
Cash conversion	164	112	122	162	186	171	166	
WC as % of revenue	45.0	30.7	33.4	44.3	50.9	46.7	45.4	

Source: Company data, I-Sec research

Exhibit 17: CFO to grow at CAGR of 47.4% over FY25–27E; FCF to turn positive in FY27E

INR mn	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	CAGR (%) FY25-27E
Ops CF (after tax & lease)	7,778	9,934	16,183	7,614	9,430	14,553	17,069	34.5
% of EBITDA	115.6	85.0	82.3	83.9	81.5	81.9	82.4	
Chg of WC	(1,642)	(2,543)	(8,827)	(1,440)	(4,150)	(6,196)	(5,600)	
CFO	6,136	7,390	7,356	6,174	5,280	8,357	11,469	47.4
% of revenue	23.2	18.7	12.9	14.4	11.1	13.9	16.3	
Capex (incl acquisition)	(2,737)	(6,740)	(6,750)	(9,669)	(8,700)	(15,190)	(7,595)	
FCF	3,400	650	606	(3,495)	(3,420)	(6,833)	3,874	
% of revenue	12.8	1.6	1.1	(8.2)	(7.2)	(11.4)	5.5	
Finance cost	(1,125)	(870)	(1,336)	(1,406)	(1,800)	(1,584)	(1,761)	
FCFE	2,274	(220)	(729)	(4,901)	(5,220)	(8,418)	2,112	

Source: Company data, I-Sec research

Peer Comparison**Exhibit 18: Specialty chemicals coverage valuation snapshot**

INR mn	CMP (INR)	Mcap (INR bn)	Revenue			CAGR (%) FY25-27E	EPS (INR)			CAGR (%) FY25-27E
			FY25A	FY26E	FY27E		FY25A	FY26E	FY27E	
SRF	2,990	886	1,46,931	1,71,964	1,90,832	14%	42.2	67.8	82.0	39%
Navin Fluorine	4,595	228	23,494	31,394	36,708	25%	58.2	91.7	111.1	38%
Gujarat Fluoro	3,968	436	47,370	60,158	70,378	22%	49.7	87.0	98.4	41%
Atul Ltd	7,042	207	55,834	68,654	77,647	18%	164.3	228.9	277.8	30%
Deepak Nitrite	1,908	260	83,792	1,00,714	1,11,234	15%	47.2	63.1	70.7	22%
Chemplast	407	64	43,461	52,142	54,553	12%	(7.2)	9.0	14.0	
Galaxy	2,277	81	42,237	48,296	49,155	8%	86.0	101.7	117.1	17%
Rossari	691	38	20,803	24,648	28,752	18%	24.6	27.2	36.9	22%
EPL	198	63	42,133	46,471	51,365	10%	11.2	13.9	16.0	20%
Sudarshan	1,049	73	28,050	32,144	35,025	12%	24.6	36.7	41.5	30%
Tatva Chintan	722	17	3,827	5,529	6,981	35%	2.4	31.0	40.1	305%
Clean Science	1,329	141	9,666	12,913	17,011	33%	24.9	31.7	38.8	25%
BlueJet Healthcare	630	109	10,300	12,583	14,339	18%	17.6	20.4	22.3	13%
Archean Chemical	602	74	10,410	16,633	18,919	35%	13.1	35.7	41.6	78%
PCBL	369	139	84,043	91,191	98,235	8%	13.3	14.2	18.7	19%
Himadri	462	228	46,126	55,990	69,027	22%	11.3	14.3	16.5	21%
Median						18%				25%

Source: I-Sec research, Company data

Exhibit 19: Specialty chemicals coverage valuation snapshot


INR mn	PE (x)		EV/EBITDA (x)		ROCE (pre-tax)		GB turnover (x)		Capex (INR mn)	
	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
SRF	44.1	36.5	24.9	21.1	16.2	17.4	0.8	0.8	25,379	24,404
Navin Fluorine	50.1	41.4	29.6	25.1	15.2	16.5	0.8	0.9	5,000	5,250
Gujarat Fluoro	45.6	40.3	25.9	22.1	13.8	14.0	0.8	0.9	15,190	7,595
Atul Ltd	30.8	25.3	16.6	13.9	14.0	15.4	1.4	1.5	3,000	2,700
Chemplast	30.2	27.0	19.8	19.6	17.5	14.0	2.5	2.7	16,575	31,654
Galaxy	45.5	29.1	14.3	12.3	9.9	11.6	1.1	1.1	2,800	2,940
Rossari	22.4	19.4	13.5	11.5	16.1	16.7	2.5	2.4	1,500	1,650
EPL	25.4	18.7	13.6	10.8	14.8	17.5	2.4	2.4	2,570	953
Sudarshan	14.3	12.3	6.8	5.9	19.4	20.6	1.0	1.0	3,800	3,500
Tatva Chintan	28.6	25.3	14.7	12.9	19.7	19.7	1.5	1.6	1,000	1,000
Clean Science	23.3	18.0	14.2	11.4	10.1	11.2	0.8	0.8	1,121	1,534
BlueJet Healthcare	41.9	34.2	28.7	23.3	26.5	27.7	1.1	1.3	2,998	1,100
Archean Chemical	30.9	28.3	23.4	20.9	34.2	31.9	2.2	2.1	2,000	1,000
PCBL	16.9	14.5	11.2	9.1	24.6	24.1	0.9	1.0	1,000	1,100
Himadri	26.0	19.7	12.6	10.4	9.9	11.9	1.7	1.6	6,000	7,000
Median	30.2	25.3	14.7	12.9	16.1	16.7	1.1	1.3		

Source: I-Sec research, Company data

Exhibit 20: Shareholding pattern

%	Sep'24	Dec'24	Mar'25
Promoters	62.6	62.6	62.6
Institutional investors	14.5	14.7	15.3
MFs and others	7.7	7.5	7.4
FIs/Banks	0.0	0.0	0.0
Insurance	1.2	1.8	2.3
FII	5.6	5.4	5.6
Others	22.9	22.7	22.1

Source: Bloomberg, I-Sec research

Exhibit 21: Price chart

Source: Bloomberg, I-Sec research

Financial Summary

Exhibit 22: Profit & Loss

(INR mn, year ending March)

	FY25A	FY26E	FY27E	FY28E
Net Sales	47,370	60,158	70,378	81,750
Operating Expenses	35,800	42,383	49,665	56,722
EBITDA	11,570	17,775	20,712	25,027
EBITDA Margin (%)	24.4	29.5	29.4	30.6
Depreciation & Amortization	3,550	4,014	5,132	5,378
EBIT	8,020	13,761	15,581	19,649
Interest expenditure	1,470	1,584	1,761	1,761
Other Non-operating Income	580	609	639	671
Recurring PBT	7,130	12,785	14,459	18,559
Profit / (Loss) from Associates	-	-	-	-
Less: Taxes	1,670	3,222	3,644	4,677
PAT	5,460	9,563	10,815	13,882
Less: Minority Interest	-	-	-	-
Extraordinaries (Net)	-	-	-	-
Net Income (Reported)	5,460	9,563	10,815	13,882
Net Income (Adjusted)	5,460	9,563	10,815	13,882

Source Company data, I-Sec research

Exhibit 23: Balance sheet

(INR mn, year ending March)

	FY25A	FY26E	FY27E	FY28E
Total Current Assets	40,040	47,885	56,616	71,537
of which cash & cash eqv.	2,220	1,433	2,774	8,570
Total Current Liabilities & Provisions	9,320	11,601	13,329	15,206
Net Current Assets	30,720	36,284	43,287	56,330
Investments	2,900	110	110	110
Net Fixed Assets	55,640	66,816	69,279	67,699
ROU Assets	1,900	1,900	1,900	1,900
Capital Work-in-Progress	15,240	15,240	15,240	15,240
Total Intangible Assets	520	520	520	520
Other assets	4,790	5,030	5,281	5,545
Deferred Tax Assets	60	60	60	60
Total Assets	1,06,090	1,22,625	1,34,123	1,47,785
Liabilities				
Borrowings	19,880	24,880	24,880	24,880
Deferred Tax Liability	2,400	2,400	2,400	2,400
Provisions	610	830	1,002	1,195
Other Liabilities	890	1,130	1,322	1,536
Equity Share Capital	110	110	110	110
Reserves & Surplus	72,420	81,215	90,620	1,01,998
Total Net Worth	72,530	81,325	90,729	1,02,108
Minority Interest	460	460	460	460
Total Liabilities	1,06,090	1,22,625	1,34,123	1,47,785

Source Company data, I-Sec research

Exhibit 24: Quarterly trend

(INR mn, year ending March)

	Jun-24	Sep-24	Dec-24	Mar-25
Net Sales	11,760	11,880	11,480	12,250
% growth (YOY)	(2.8)	25.5	15.8	8.1
EBITDA	2,620	2,950	2,940	3,060
Margin %	22.3	24.8	25.6	25.0
Other Income	90	90	140	260
Extraordinaries	0	0	0	0
Adjusted Net Profit	1,080	1,210	1,260	1,910

Source Company data, I-Sec research

Exhibit 25: Cashflow statement

(INR mn, year ending March)

	FY25A	FY26E	FY27E	FY28E
Operating Cashflow	9,600	14,553	17,069	20,350
Working Capital Changes	(4,150)	(6,196)	(5,600)	(7,163)
Capital Commitments	(8,190)	(15,190)	(7,595)	(3,798)
Free Cashflow	(2,740)	(6,833)	3,874	9,390
Other investing cashflow	(2,620)	3,399	639	671
Cashflow from Investing Activities	(2,500)	3,399	639	671
Issue of Share Capital	-	-	-	-
Interest Cost	(1,800)	(1,584)	(1,761)	(1,761)
Inc (Dec) in Borrowings	(90)	5,000	-	-
Dividend paid	(330)	(769)	(1,410)	(2,504)
Others	8,380	-	-	-
Cash flow from Financing Activities	5,990	2,647	(3,172)	(4,266)
Chg. in Cash & Bank balance	240	(787)	1,342	5,795
Closing cash & balance	550	1,433	2,774	8,570

Source Company data, I-Sec research

Exhibit 26: Key ratios

(Year ending March)

	FY25A	FY26E	FY27E	FY28E
Per Share Data (INR)				
Reported EPS	49.7	87.0	98.4	126.3
Adjusted EPS (Diluted)	49.7	87.0	98.4	126.3
Cash EPS	82.0	123.5	145.1	175.3
Dividend per share (DPS)	3.0	7.0	12.8	22.8
Book Value per share (BV)	664.1	744.2	829.7	933.3
Dividend Payout (%)	6.0	8.0	13.0	18.0
Growth (%)				
Net Sales	10.7	27.0	17.0	16.2
EBITDA	27.5	53.6	16.5	20.8
EPS (INR)	25.5	75.2	13.1	28.4
Valuation Ratios (x)				
P/E	80.3	45.8	40.5	31.6
P/CEPS	48.6	32.3	27.5	22.8
P/BV	6.0	5.4	4.8	4.3
EV / EBITDA	39.2	26.0	22.2	18.2
EV/SALES	9.6	7.7	6.5	5.6
Dividend Yield (%)	0.1	0.2	0.3	0.6
Operating Ratios				
Gross Profit Margins (%)	68.1	69.1	68.1	67.1
EBITDA Margins (%)	24.4	29.5	29.4	30.6
Effective Tax Rate (%)	23.4	25.2	25.2	25.2
Net Profit Margins (%)	11.5	15.9	15.4	17.0
NWC / Total Assets (%)	29.0	29.6	32.3	38.1
Net Debt / Equity (x)	0.2	0.3	0.2	0.2
Net Debt / EBITDA (x)	1.3	1.3	1.1	0.7
Profitability Ratios				
RoCE (%)	7.1	10.3	10.5	12.1
RoE (%)	8.3	12.4	12.6	14.4
RoIC (%)	7.4	10.7	10.7	12.7
Fixed Asset Turnover (x)	0.8	0.8	0.9	0.9
Inventory Turnover Days	140.2	130.0	130.0	130.0
Receivables Days	92.2	87.2	82.2	82.2
Payables Days	46.7	46.7	46.7	46.7

Source Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com and Kadambari_balachandran@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)
BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We, Sanjesh Jain, PGDM; Mohit Mishra, MBA, CA; Aparajita Chakraborty M.Sc. (Finance); authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, **E-mail Address :** complianceofficer@icicisecurities.com

For any queries or grievances: [Mr. Bhavesh Soni](mailto:Mr_Bhavesh_Soni@icicidirect.com) Email address: headservicequality@icicidirect.com Contact Number: 18601231122
